François Richard, Marion Maetens, Karen Van Baelen, Kristien Borremans, Josephine Van Cauwenberge, Gitte Zels, E. Rousseau, Tatjana Geukens, Maxim De Schepper, Amena Mahdami, Evy Vanderheyden, Thomas Van Brussel, Ha-Linh Nguyen, Anirudh Pabba, Sophia Leduc, Hava Izci, Imane Bachir, C. Carette, Sigrid Hatse, Madita Nysen, Peter Vermeulen, Bram Boeckx, Diether Lambrechts, Elia Biganzoli, Patrick Neven, Hans Wildiers, Wouter Van Den Bogaert, Jonas Demeulemeester, Giuseppe Floris, Christine Desmedt
Liquid biopsies enable non-invasive monitoring and characterization of metastatic cancer, primarily through circulating tumor DNA (ctDNA) in blood. The representativeness of all metastatic sites in these liquid biopsies and the clinical relevance of other body fluids remain uncertain. We performed low-pass whole genome sequencing on 216 liquid and 745 metastatic tissue samples from 20 autopsied female patients with metastatic breast cancer to assess ctDNA detection, fraction, and site representativeness in seven body fluids (blood, ascites, cerebrospinal fluid, pericardial fluid, pleural fluid, saliva, and urine). Complementarily, whole exome sequencing on 86 liquid samples from 11 patients explored mutational information. ctDNA was detected in all fluids, but most frequently in blood, followed by ascites, pleural fluid, and cerebrospinal fluid. Phylogenetic reconstruction indicated that site representativeness varies by fluid type. Mutational and gene-level copy number analyses revealed clinically relevant information unique to non-blood fluids. These findings suggest a multi-fluid approach could enhance metastatic cancer monitoring and characterization. Liquid biopsy methods have mainly been focused on the use of peripheral blood, and comparison between body fluids has been limited. Here, the authors utilize samples from a rapid tissue donation program to compare body fluid sites in their representativeness of the metastatic disease in patients with breast cancer.